• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Topcon to Accelerate Growth through Management Buyout with KKR and JIC Capital

    3/28/25 5:22:00 AM ET
    $KKR
    Investment Managers
    Finance
    Get the next $KKR alert in real time by email

    Powerful combination of KKR and JICC creates stable foundations for Topcon to pursue long-term growth

    Topcon Corporation ("Topcon" or the "Company"; TSE stock code 7732) today announced that it is launching a management buyout ("MBO") led by Topcon President and CEO Takashi Eto. The MBO will receive investment from funds managed by KKR, a leading global investment firm, and JIC Capital ("JICC"), a wholly owned subsidiary of Japan Investment Corporation ("JIC"). In connection with the MBO, TK Co., Ltd. (the "Offeror"), an entity owned by investment funds managed by KKR, intends to make a tender offer for the common shares and share acquisition rights, etc. of the Company. Topcon's Board of Directors has resolved to support this tender offer and recommends that shareholders and share acquisition right holders tender their securities.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327998023/en/

    The tender offer price will be JPY 3,300 per share, determined after negotiations between KKR and Topcon.

    The proposed tender offer price represents1:

    • A 99.5% premium over the simple average closing price of Topcon's stock for the 12 months up to December 9, 2024; and
    • A 105.2% premium over the simple average closing price of Topcon's stock for the 6 months up to December 9, 2024.

    KKR is making this investment predominantly from its Asian Fund IV, and it is planned that KKR will indirectly hold a majority interest in Topcon. Following the completion of the tender offer, JICC intends to indirectly hold voting rights in Topcon through JIC PE Fund No. 1 and JIC PE Co-Investment Fund No. 1, investment limited partnerships managed by JICC. Topcon President and CEO Takashi Eto also intends to participate in the tender offer and plans to make a reinvestment after the completion of the tender offer; the details of his investment are yet to be determined.

    Topcon is pursuing its long-term vision leading up to its 100th anniversary in 2032, and the Company has been implementing its "Mid-Term Management Plan 2025" covering the fiscal years 2023–2025. Under this plan, Topcon has pursued sustainable business growth and improved profitability by deepening its orientation towards customers, and as the next step, the Company aims to evolve into "New Topcon 2.0," a business structure that will further accelerate the competitiveness of the Topcon Group. In particular, to transform its eye care business from a hardware-based business to a solutions business, and to achieve further growth in its positioning business, where the competitive environment is rapidly changing, the Company believes that bold, long-term investments and fundamental transformations beyond conventional business reforms are necessary.

    Following an in-depth evaluation of all options, Topcon concluded that a management buyout in strategic partnership with KKR and JICC offers the Company the best path to achieve its long-term objectives and enhance its corporate value to benefit all stakeholders, including shareholders. Topcon's competitive edge lies in the combination of its advanced hardware design and manufacturing capabilities, rooted in Japanese craftsmanship, and its rapidly growing solutions business, particularly in the United States. Topcon believes that it is essential to develop an agile corporate structure to undertake bold investments and implement long-term initiatives. As a private company, the strategic partnership and patient capital support from KKR and JICC will enable Topcon to stay agile, undertake the bold investments and implement the long-term initiatives needed to accelerate its growth and strengthen its competitiveness. Topcon's current management team will continue to operate the Company and work with its shareholders to implement management initiatives to efficiently and quickly achieve its long-term goals.

    Additionally, Topcon leverages its cutting-edge optical technology to develop and manufacture products for the space and defense industry, which is critical to Japan's national security. Therefore, JICC's investment will help the Company to develop these business areas and increase its value in the long term.

    For KKR, Japan is a key market for its Asia Pacific and global strategy; it has around $18 billion in assets under management in the country. In the ophthalmology sector related to Topcon's business, KKR has a long track record, including National Vision, an optical retailer in the US; nexeye, a provider of value-for-money eye care in Europe; and Lenskart, an omni-channel eyewear retailer in India, and in the adjacent construction and civil engineering fields within the industrial sector, GeoStabilization International, a provider of geohazard mitigation solutions and roadway safety services in the US. KKR looks to support Topcon's growth after the privatization by leveraging its global network, deep operational expertise and investment experience in the ophthalmology, healthcare, and industrial sectors to share best practices and help Topcon expand internationally, including in the US, a priority market.

    JICC, as a government-affiliated fund, has built deep public-private networks and operational know-how through extensive investment experience in Japan and overseas. JICC will support Topcon's transformation into a global solutions company centered on its eye care business, which will contribute to the creation of new industries and strengthen international competitiveness, and JICC will support this due to its policy significance. In particular, JICC's long-term, neutral funds will be essential to support Topcon's long-term structural reforms and growth strategies. Also, JICC will complement KKR's private markets expertise, with this combination of public and private funds providing medium- to long-term risk sharing and strong capital and credit alignment.

    Takeshi Eto, President and CEO of Topcon, said "Today's announcement represents a crucial step in realizing "Topcon 2.0" and in achieving our long-term vision and to drive future growth. Strategically partnering with KKR and JICC will enable us to focus on bold, agile investments and management initiatives, including structural reforms, without being constrained by potential short-term uncertainties. I am confident that our close alignment between the management team and our future shareholders for this MBO will enable us to address mid- to long-term challenges together, implement management initiatives more effectively, and accelerate our business expansion."

    Hiro Hirano, Deputy Executive Chairman of KKR Asia Pacific and CEO of KKR Japan, said, "We have long admired Topcon's strong product offering and are delighted to have the opportunity to invest behind their long-term global ambitions. As like-minded strategic partners, we are also pleased to join forces with JICC, who possess a deeply unique understanding of Japan and Topcon's critical sectors and equal commitment towards the Company's success. We look forward to collaborating closely with Mr. Eto and his talented management team and JICC to help Topcon accelerate its growth, including through our global network of industry experts and portfolio companies, and achieve its goal of becoming a leading global solutions company."

    Shogo Ikeuchi, President and CEO of JIC Capital, said, "This transaction and joint investment with KKR marks a significant milestone for JICC. We believe that this strategic partnership between our three companies will certainly enhance the stability of Topcon's management, while at the same time paving the way for KKR to contribute significantly to Topcon's business. KKR has unique strengths that other investors and companies cannot achieve, and by making the most of KKR's outstanding strategic insights and resources, we are confident that Topcon will be able to achieve sustainable, stable growth and strengthen its leadership in the global market. Topcon is an excellent example of Japan's manufacturing prowess, and JICC aims to be a strong partner for Topcon to continue to grow its business in Japan and achieve its bold corporate strategy to transform from a hardware company to a global solutions business with significant overseas growth."

    The tender offer is expected to commence around the end of July 2025, subject to the satisfaction or waiver of certain conditions precedent, including regulatory approvals in Japan and other jurisdictions. For details regarding the conditions of the commencement of the tender offer, please refer to the full text of the release issued by the Offeror today titled, "Notice Regarding the Planned Commencement of Tender Offer for the Shares of Topcon Corporation (Securities Code: 7732) by TK Co., Ltd. as part of the MBO Implementation and Capital Participation by KKR and JICC."

    Forward-looking Statements

    This press release should be read in conjunction with the release issued by the Offeror today titled "Notice Regarding the Planned Commencement of Tender Offer for the Shares of Topcon Corporation (Securities Code: 7732) by TK Co., Ltd. as part of the MBO Implementation and Capital Participation by KKR and JICC".

    The purpose of this press release is to publicly announce the tender offer and it has not been prepared for the purpose of soliciting an offer to sell or purchase in the tender offer. When making an application to tender, please be sure to read the Tender Offer Explanatory Statement for the tender offer and make your own decision as a shareholder or share acquisition right holder. This press release does not constitute, either in whole or in part, a solicitation of an offer to sell or purchase any securities, and the existence of this press release (or any part thereof) or its distribution shall not be construed as a basis for any agreement regarding the tender offer, nor shall it be relied upon in concluding an agreement regarding the tender offer.

    The tender offer will be conducted in compliance with the procedures and information disclosure standards set forth in Japanese law, and those procedures and standards are not always the same as the procedures and information disclosure standards in the U.S. In particular, neither Sections 13(e) or 14(d) of the U.S. Securities Exchange Act of 1934 (as amended; the same shall apply hereinafter) or the rules under these sections apply to the tender offer; and therefore the tender offer is not conducted in accordance with those procedures and standards. In addition, because the tender offer is a corporation incorporated outside the U.S., it may be difficult to exercise rights or demands against them that can be asserted based on U.S. securities laws. It also may be impossible to initiate an action against a corporation that is based outside of the U.S. or its officers in a court outside of the U.S. on the grounds of a violation of U.S. securities-related laws. Furthermore, there is no guarantee that a corporation that is based outside of the U.S. or its affiliates may be compelled to submit themselves to the jurisdiction of a U.S. court.

    Unless otherwise specified, all procedures relating to the tender offer are to be conducted entirely in Japanese. All or a part of the documentation relating to the tender offer will be prepared in English; however, if there is any discrepancy between the English-language documents and the Japanese-language documents, the Japanese-language documents shall prevail.

    This press release includes statements that fall under "forward-looking statements" as defined in Section 27A of the U.S. Securities Act of 1933 (as amended) and Section 21E of the Securities Exchange Act of 1934. Due to known or unknown risks, uncertainties or other factors, actual results may differ materially from the predictions indicated by the statements that are implicitly or explicitly forward-looking statements. Neither the Offeror nor any of its affiliates guarantee that the predictions indicated by the statements that are implicitly or expressly forward-looking statements will materialize. The forward-looking statements in this press release were prepared based on information held by the Offeror as of today, and the Offeror and its affiliates shall not be obliged to amend or revise such statements to reflect future events or circumstances, except as required by laws and regulations.

    The Offeror, its and the Company's respective financial advisors and the tender offer agent (and their respective affiliates) may purchase the common shares and share options of the Company, by means other than the tender offer, or conduct an act aimed at such purchases, for their own account or for their client's accounts, including in the scope of their ordinary business, to the extent permitted under financial instrument exchange-related laws and regulations, and any other applicable laws and regulations in Japan, in accordance with the requirements of Rule 14e-5(b) of the U.S. Securities Exchange Act of 1934 during the tender offer period. Such purchases may be conducted at the market price through market transactions or at a price determined by negotiations off-market. In the event that information regarding such purchases is disclosed in Japan, such information will also be disclosed on the English website of the person conducting such purchases (or by any other method of public disclosure).

    If a shareholder exercises its right to demand the purchase of shares of less than one unit in accordance with the Companies Act, the Company may buy back its own shares during the tender offer period in accordance with the procedures required by laws and regulations.

    About Topcon Corporation

    Topcon Corporation is a global leader in the manufacturing of technology designed to address the essential challenges society faces in healthcare, agriculture, and infrastructure. Topcon specializes in developing optical, sensing and control solutions powered by leading digital transformation technologies for these industries. For more information about Topcon (Tokyo Stock Exchange: 7732), visit: www.global.topcon.com

    About KKR

    KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.

    About JIC Capital

    JIC Capital aims to supply risk capital to achieve policy objectives of creating new businesses and industries to realize Society 5.0, promoting business portfolio transformation for enhancing the international competitiveness, and establishing next-generation social infrastructure to promote Digital Transformation ("DX").

    1 Based on the closing price of Topcon on December 9, 2024, the day before speculative media reporting about the bidding process that impacted the Company's share price.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250327998023/en/

    Media Inquiries

    For Topcon Corporation

    Takaaki Hirayama

    +81-3-3558-2568 (Media) and +81-3-3558-2532 (Investors)

    For KKR

    Wei Jun Ong

    +65 6922 5813

    [email protected]

    For JIC Capital

    Communications Group

    [email protected]

    Get the next $KKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KKR

    DatePrice TargetRatingAnalyst
    2/24/2026$137.00Outperform
    RBC Capital Mkts
    1/28/2026$144.00Hold → Buy
    HSBC Securities
    1/14/2026$131.00Buy → Hold
    TD Cowen
    12/11/2025$176.00Buy
    UBS
    7/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/9/2025$142.00Buy → Hold
    HSBC Securities
    6/30/2025$150.00Overweight
    Piper Sandler
    5/14/2025$150.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $KKR
    SEC Filings

    View All

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    3/2/26 8:32:24 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    2/27/26 5:01:59 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    2/27/26 5:00:39 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on KKR with a new price target

    RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00

    2/24/26 7:55:00 AM ET
    $KKR
    Investment Managers
    Finance

    KKR upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00

    1/28/26 7:11:28 AM ET
    $KKR
    Investment Managers
    Finance

    KKR downgraded by TD Cowen with a new price target

    TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00

    1/14/26 8:26:34 AM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KKR Income Opportunities Fund Declares Monthly Distributions of $0.1215 Per Share

    KKR Income Opportunities Fund (the "Fund") (NYSE:KIO) today announced its monthly distributions of $0.1215 per common share, payable on the dates below. Based on the Fund's current share price of $11.04 per share (as of market close on March 9, 2026), the distributions represent an annualized distribution rate of 13.21%, (calculated by annualizing the distribution amount and dividing it by the current price). The monthly distribution schedule is as follows for the months of April, May, and June: Ex-Date: April 10, 2026 Record Date: April 10, 2026 Payable Date: April 30, 2026     Ex-Date: May 8, 2026 Record Date:

    3/10/26 5:23:00 PM ET
    $KIO
    $KKR
    Investment Managers
    Finance

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    KKR to Present at the 2026 RBC Capital Markets Financial Institutions Conference

    KKR & Co. Inc. (NYSE:KKR) announced today that Robert H. Lewin, Chief Financial Officer, will present at the 2026 RBC Capital Markets Financial Institutions Conference on Wednesday, March 11, 2026 at 9:20AM ET. A live webcast of the presentation will be available on the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. For those unable to listen to the live webcast, a replay will be available on the website shortly after the event. Any questions regarding the webcast may be addressed to KKR's Investor Relations team at [email protected]. ABOUT KKR KKR is a leading global investment firm that offers alternative asset management as well as

    2/26/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Director Dillon Mary N bought $2,021,586 worth of shares (22,225 units at $90.96) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:01 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Kkr Group Partnership L.P.

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    3/10/26 5:15:24 PM ET
    $KKR
    Investment Managers
    Finance

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Kkr Group Partnership L.P. sold $807,546,115 worth of shares (19,715,000 units at $40.96), disposed of 402,773 shares and gifted 81,213 shares (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    3/4/26 7:46:52 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    KKR-led Consortium Drives Further Investment in Sylvan

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance

    Peak Re Welcomes KKR and Quadrantis Capital as Minority Investors

    Peak Reinsurance Company Limited ("Peak Re" or the "Company") and KKR, a leading global investment firm, today announced that funds managed by KKR and Quadrantis Capital have entered into definitive agreements to acquire minority stakes in Peak Re via Peak Reinsurance Holdings Limited. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020924186/en/ Upon completion, KKR and Quadrantis Capital are expected to hold approximately 11.27% and approximately 1.80% of Peak Re's issued share capital, respectively, with the remaining approximately 86.71% continuing to be held by the majority shareholder, Fosun International Limited. Pruden

    10/20/25 9:05:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Appoints Craig Arnold to Board

    KKR & Co. Inc. (NYSE:KKR) today announced that Craig Arnold has been appointed to the Board of Directors effective September 23, 2025. His appointment will bring the number of independent directors to eleven out of a total of fifteen Board seats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924641078/en/Craig Arnold Mr. Arnold is the former Chairman and Chief Executive Officer of Eaton Corporation, a global intelligent power management company. KKR's other Board members are: Henry Kravis (Co-Founder and Co-Executive Chairman of KKR), George Roberts (Co-Founder and Co-Executive Chairman of KKR), Joseph Bae (Co-Executive Of

    9/24/25 4:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/4/24 11:48:27 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G/A filed by KKR & Co. Inc. (Amendment)

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    2/13/24 6:32:37 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Financials

    Live finance-specific insights

    View All

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    FS KKR Capital Corp. Announces Fourth Quarter and Full Year 2025 Results; Declares First Quarter 2026 Distribution of $0.48 per Share

    PHILADELPHIA and NEW YORK, Feb. 25, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK), or the Company, today announced its financial and operating results for the quarter and year ended December 31, 2025, and that its board of directors has declared a first quarter 2026 distribution of $0.48 per share. Financial and Operating Highlights for the Quarter Ended December 31, 2025(1)Net investment income of $0.48 per share, compared to $0.57 per share for the quarter ended September 30, 2025Adjusted net investment income(2) of $0.52 per share, compared to $0.57 per share for the q

    2/25/26 4:15:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    Keurig Dr Pepper Announces Updated Financing Plan for JDE Peet's Acquisition

    Company strengthens balance sheet by further reducing projected leverage and attracts additional high-quality investorsBURLINGTON, Mass. and FRISCO, Texas, Feb. 23, 2026 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ:KDP, ", the Company", )) today announced updated financing plans and transaction timelines for the acquisition of JDE Peet's and subsequent planned separation into two independent companies ("Beverage Co." and "Global Coffee Co." pending the announcement of official corporate names).Key developments include:A targeted close of the JDE Peet's acquisition in early April 2026, with expected combined net leverage of approximately 4.5x1An agreement to upsize the previously announced B

    2/23/26 4:30:00 PM ET
    $APO
    $KDP
    $KKR
    Investment Managers
    Finance
    Beverages (Production/Distribution)
    Consumer Staples